Algiax Pharmaceuticals has begun enrolling patients in a Phase IIa Proof-of-Concept Study evaluating GABAA receptor modulator, AP-325, in Chronic Neuropathic Pain

Algiax Pharmaceuticals, a clinical-stage biotechnology company developing GABAA receptor modulators for neuropathic pain and other indications, announced that it has begun enrolling patients in the CURE study.

The CURE study is a randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of Algiax´ lead molecule AP-325 (a small-molecule positive allosteric modulator of GABAA receptor) in patients with chronic post-surgical neuropathic pain.

Top-line Data for the “CURE” Study Anticipated in Fourth Quarter 2021

Previously, the company has raised 5.5 million Euro to advance its development program, including the CURE study (read the press release here).

Along with AP-325, Algiax is advancing a selection of novel GABAA receptor modulator compounds called Thioacrylamide (ThAc) derivatives. The main focus area for these novel compounds will be the treatment of diabetes.

Read the press release here.

Read more about Algiax Pharmaceuticals here.

Image by Tumisu from Pixabay